ESMO Press Releases

The ESMO Immuno-Oncology Congress 2021, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held as an onsite and online congress.

Results of the ESMO Women for Oncology monitoring and authorship studies

The much-anticipated ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer has been published today in Annals of Oncology.

Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.

First concrete results presented at the ESMO Congress 2021 confirm need to promote vaccination in patients with cancer

FIRSTMAPPP, the first randomised study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months

The PEACE-1 and STAMPEDE studies found that the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy lengthened survival compared to standard therapy alone.

Adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with hormone receptor (HR) positive, HER2 negative advanced breast cancer, according to late breaking results of the MONALEESA-2 trial

The addition of immunotherapy to standard first-line treatment extends survival by eight months

The first randomised phase III clinical trial in stage II melanoma has shows a 35% reduction in the risk of recurrence with adjuvant pembrolizumab compared with placebo

Study shows that a significant proportion of survivors continue to suffer from burdensome symptoms for several years

Two studies [to be] presented at the ESMO Congress 2021 suggest a need for broader education on current standards of cancer care